RE: Trust6 Jun 2022 16:37
In March trading update & presentation CF stated Revenue for 2021 c£40m, with cash at £15.6m. He also guided 2022 Revenue c£50m excluding any Covid work. Since that update he has announced 5 contract wins; March - £5m human challenge Study Contract, May - Challenge virus manufacturing contract, Vaccine field study contract, £7.3m influenza human challenge study, June - £14.7m Influenza contract.
EBITDA profitability is EBITDA in my books. CASH is king for me in any growth company.
What I'm looking for in tomorrow's update is are we on track to meet or exceed the c£50m revenue for 2022 and if yes by how much. Also what is our cash position likely to be for Dec 2022? This will give us an idea of how much of the weighted pipeline is in for 2022 versus 2023.
We also have a 6pm presentation of the results tomorrow where we can ask for more details if they are not explicit in the results announcement.
Roll on tomorrow - GLA